doi: 10.3389/fmicb.2024.1403168 51 SkodowskiK.ChmielewskaS
Its structure features two key modifications that set it apart: An arginine substitution at the third position A 13-amino acid extension at the N-terminus This unique molecular architecture results in a more stable compound with a molecular weight of approximately 9.1 kDa, specifically designed to optimize its performance within the human body
In most cases, these changes are thought to be related to weight loss, hormonal adjustments, improved insulin sensitivity, and changes in ovulation rather than a direct effect of the medication on the menstrual cycle
These medications, alongside specialty treatments like nutritional testing, detox protocols, and vitamin therapy, empower patients to improve both their weight and overall health
CV outcome trials demonstrated reductions in atherothrombotic events, especially in patients with established atherosclerosis 13